Targeting TDP-43 in ALS: Regulatory hurdles, trial design deficiencies, and the causal evidence gap for CTx1000

Area of Science:

• Neuroscience
• Molecular Biology
• Clinical Pharmacology

Background:

• Amyotrophic lateral sclerosis (ALS) has a history of clinical trial failures due to heterogeneity and poor target engagement.
• TAR DNA-binding protein 43 (TDP-43) aggregation is a key pathological hallmark in most ALS cases.
• Precision medicine approaches are emerging to target the underlying TDP-43 pathology.

Purpose of the Study:

• To critically evaluate historical regulatory hurdles and trial design deficiencies in ALS clinical development.
• To review the potential of novel precision medicine modalities, such as PROTAC CTx1000, for targeting TDP-43.
• To incorporate the dual sequestration hypothesis to understand TDP-43 pathology convergence in neurodegenerative diseases.

Main Methods:

• Literature review of ALS clinical trial failures and regulatory landscapes.
• Analysis of TAR DNA-binding protein 43 (TDP-43) aggregation as a therapeutic target.
• Incorporation of the dual sequestration hypothesis for neurodegenerative disease pathology.

Main Results:

• Decades of ALS clinical trials have been hampered by biological heterogeneity, insensitive endpoints, and lack of target engagement data.
• Proteolysis-targeting chimeras (PROTACs), like CTx1000, offer a technological advance for selective TDP-43 degradation.
• The dual sequestration hypothesis provides a framework for understanding TDP-43's role across neurodegenerative conditions.

Conclusions:

• Rigorous biomarker-led methodologies are essential for future ALS clinical development.
• Target-specific degraders represent a significant technological leap but require addressing knowledge gaps in target engagement and trial design.
• Understanding age-dependent vector tropism and optimizing trial architecture are critical for the success of novel ALS therapeutics.